Page 3 - பாலியல் மற்றும் இனப்பெருக்கம் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பாலியல் மற்றும் இனப்பெருக்கம் ஆரோக்கியம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பாலியல் மற்றும் இனப்பெருக்கம் ஆரோக்கியம் Today - Breaking & Trending Today

Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch


Press release content from Business Wire. The AP news staff was not involved in its creation.
Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch
February 19, 2021 GMT
HAYWARD, Calif. (BUSINESS WIRE) Feb 19, 2021
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first CellFX ® procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear common benign lesions, now expands the Company’s controlled launch program starting with the top aesthetic dermatologists and plastic surgeons across Europe. This strategic rollout in Europe will run in parallel with the Company’s U.S. controlled launch aimed at building a strong foundation of clinical and commercial advocacy as the Company grows a promising global business. ....

United States , Afschin Fatemi , Ted Ebbers , Nadined Tosk , Sandra Gardiner , Tosk Communications , Exchange Commission , Pulse Biosciences Inc , European Union , Gilmartin Group , Health Canada , Nano Pulse Stimulation , Business Wire , S Thetic Group , Executive Vice President , General Manager , Pulse Biosciences , Pulse Stimulation , Pulse Bioscience , Products And Services , Government Regulations , Product Approvals , Hpv Infections , Sexually Transmitted Diseases , Sexual And Reproductive Health , New Products And Services ,

Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant .
Sumitovant BiopharmaFebruary 18, 2021 GMT
New York, London, Feb. 17, 2021 (GLOBE NEWSWIRE) Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that the New England Journal of Medicine published Myovant Sciences’ Phase 3 LIBERTY 1 and LIBERTY 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with uterine fibroids.  As previously reported, both studies achieved the primary endpoint of response rates in menstrual blood loss in addition to six of the seven key secondary endpoints, while maintaining bone mineral density comparable to placebo as part of a well-tolerated safety profile over 24 weeks. ....

New York , United States , City Of , United Kingdom , Sumitomo Dainippon Pharma , Sumitovant Biopharma , Mary Stutts Sumitovant Biopharma , Myrtle Potter , Myovant Sciences Forward , Myovant Sciences , Dainippon Pharmaceutical Co Ltd , Exchange Commission , Altavant Sciences , Spirovant Sciences , European Union , Sumitomo Dainippon Pharma Co Ltd , Urovant Sciences , Sumitomo Pharmaceuticals Co Ltd , Sumitovant Biopharma Ltd , Biopharma Ltd , New England Journal , Myovant Science Phase , New York City , Sumitomo Dainippon , Enzyvant Therapeutics , Dainippon Pharma ,

All You Need to Know About Emergency Contraception

Sexual and reproductive health was the top consulted specialty online in 2020, with one in every four consultations from women during the year coming for sexual and reproductive health. ....

Sexual And Reproductive Health , Emergency Contraception , Pradeepkumar Sandipan Jadhavar , பாலியல் மற்றும் இனப்பெருக்கம் ஆரோக்கியம் ,